Objective
To assess satisfaction and trust related to different insulin delivery devices (IDD) in people with type 1 diabetes (T1D) before and after starting Basal-IQ® technology on the t:slim X2™ insulin pump.
Method
Participants completed an online baseline survey including questions about their IDD (prior to Basal-IQ technology). This survey was repeated after 6 months (Post-Assessment) to assess participants’ experience with Basal-IQ technology. Participants elaborated on their experiences with their IDD in open-ended items on satisfaction and trust with their devices.
Results
Overall, there was a significant increase in both satisfaction and trust related to insulin delivery device after 6 months of Basal‑IQ technology use (p<0.001). Although a significant increase in IDD satisfaction was seen across participants (irrespective of Previous IDD type) at Post- Assessment, those on multiple daily injections (MDI) reported the largest increase in satisfaction (4.8 to 9.2, 91% increase), followed by previous Medtronic users (6.3 to 8.6, 36% increase). Previous MDI, OmniPod, and Medtronic users all showed a significant increase in IDD trust at Post-Assessment.
Conclusion
This study demonstrated notable improvements in IDD-related satisfaction and trust after 6 months of Basal-IQ technology use.
Product Documentation
Consult user guides for our pumps, infusion sets, predictive technology, and reporting app.
View DocumentationProduct Training
Use our education tutorials to train your patients or CDEs on our easy-to-use products.
View ResourcesRecommending
Recommending the t:slim X2 insulin pump is easy with our customized referral process and insurance benefits check.
Learn More
Responsible Use of Basal-IQ Technology
References:
1. Forlenza GP, et al. Diabetes Care. 2018;41(10):2155-2161.
2. Editorial. Lancet Diabetes Endocrinol.
2019;7(9):657.
3. Subramanian S, et al. Diabetes Spectr. 2014;27(2):87-91.
4. Fleming GA, et al. Diabetes Care.
2020;43(1):250-260.
5. Tanenbaum ML, et al. J Diabetes Sci Technol. 2017;11(3):484-492.
6. Arafat Y, et al. The Use of
Measurements ... Present Challenges and Future Solutions [Internet]. 2018
7. Liberman A, et al. Diabetes Technol
Ther. 2016;18(Suppl 1):S101-S11.
Important Safety Information
The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the System can be used to suspend insulin delivery based on CGM sensor readings. The pump and the System are indicated for use in individuals six years of age and greater. The pump and the System are intended for single user use. The pump and the System are indicated for use with NovoRapid, Admelog, or Humalog U-100 insulin. The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.